REVIVA PHARMACEUTICALS HOLDINGS, INC. Operating Income

Quick Answer

REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Operating Income of -$20.20 million for fiscal year 2025.

REVIVA PHARMACEUTICALS HOLDINGS, INC. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$20.20M +34.4%
2024 -$30.80M +22.0%
2023 -$39.50M -39.9%
2022 -$28.23M -179.4%
2021 -$10.10M +0.0%
2021 -$10.10M -315.0%
2020 -$2.43M -235.9%
2020 -$724.7K -92.3%
2019 -$376.9K -146.7%
2019 -$152.8K

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$4.03M +52.4% +33.6%
June 30, 2025 -$6.07M +25.3% +7.1%
March 31, 2025 -$6.54M +17.5% +22.7%
September 30, 2024 -$8.46M +26.8% -4.1%
June 30, 2024 -$8.13M +28.3% -2.6%
March 31, 2024 -$7.92M -13.4% +31.5%
September 30, 2023 -$11.56M -224.6% -2.0%
June 30, 2023 -$11.34M -105.4% -62.3%
  • REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +34.4% in Operating Income compared to the prior fiscal year.
  • Over the 2019–2025 period, REVIVA PHARMACEUTICALS HOLDINGS, INC.’s operating income has declined by 13120.9% (from -$152.8 thousand to -$20.20 million).
  • The most recent figure is from REVIVA PHARMACEUTICALS HOLDINGS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment